October 17, 2019

Companion Diagnostics Expertise

Expertise that supports development of your companion diagnostic
Companion diagnostics (CDx) enable personalized medicine by identifying likely patient responders based on efficacy and safety. Guidance recommends that sponsors consider CDx early in drug development, and to plan for co-development of the product with a companion diagnostic. Q2 Solutions has successfully supported drug developers in many clinical development programs globally, from the early stages of biomarker identification through clinical trials testing and commercialization. Download the brochure to read more about our CDx services and expertise.

Related Services:
Adapting Clinical Trial Best Practices to a Complex Global CDx Landscape

World CDx Europe 2019

Companion Diagnostics with Andrew Crenshaw

I-O clinical development podcast series

Successful Companion Diagnostics Programs: Experiences of a Global Central Laboratory

World CDx Boston 2019

Read More